Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Nantes, France, 23 mars 2026 – 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE), une société de biotechnologie au stade clinique développant des thérapies first-in-class en...
-
Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit...
-
Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
-
Checkerspot announced the first microalgae-based production of high-yield palmitoleic acid (POA) oil with a study published in the Journal Fermentation.
-
SEATTLE, March 23, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for...
-
SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...
-
PharmAla provides an update on Cortexa, its Australian joint venture with Vitura Health.
-
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016,...
-
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with...
-
Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to...